Ferroptosis Inhibitors as Potential New Therapeutic Targets for Cardiovascular Disease
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Ferroptosis is a novel form of programmed cell death that occurs due to an increase in iron levels. Ferroptosis is implicated in a number of cardiovascular diseases, including myocardial infarction (MI), reperfusion damage, and heart failure (HF). As cardiomyocyte depletion is the leading cause of patient morbidity and mortality, it is critical to thoroughly comprehend the regulatory mechanisms of ferroptosis activation. In fact, inhibiting cardiac ferroptosis can be a useful therapeutic method for cardiovascular disorders. The iron, lipid, amino acid, and glutathione metabolisms strictly govern the beginning and execution of ferroptosis. Therefore, ferroptosis can be inhibited by iron chelators, free radical-trapping antioxidants, GPX4 (Glutathione Peroxidase 4) activators, and lipid peroxidation (LPO) inhibitors. However, the search for new molecular targets for ferroptosis is becoming increasingly important in cardiovascular disease research. In this review, we address the importance of ferroptosis in various cardiovascular illnesses, provide an update on current information regarding the molecular mechanisms that drive ferroptosis, and discuss the role of ferroptosis inhibitors in cardiovascular disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Mini reviews in medicinal chemistry - 22(2022), 17 vom: 06., Seite 2271-2286 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shaghaghi, Zahra [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.09.2022 Date Revised 16.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389557522666220218123404 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337165467 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337165467 | ||
| 003 | DE-627 | ||
| 005 | 20231225233805.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389557522666220218123404 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM337165467 | ||
| 035 | |a (NLM)35184711 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shaghaghi, Zahra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ferroptosis Inhibitors as Potential New Therapeutic Targets for Cardiovascular Disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.09.2022 | ||
| 500 | |a Date Revised 16.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Ferroptosis is a novel form of programmed cell death that occurs due to an increase in iron levels. Ferroptosis is implicated in a number of cardiovascular diseases, including myocardial infarction (MI), reperfusion damage, and heart failure (HF). As cardiomyocyte depletion is the leading cause of patient morbidity and mortality, it is critical to thoroughly comprehend the regulatory mechanisms of ferroptosis activation. In fact, inhibiting cardiac ferroptosis can be a useful therapeutic method for cardiovascular disorders. The iron, lipid, amino acid, and glutathione metabolisms strictly govern the beginning and execution of ferroptosis. Therefore, ferroptosis can be inhibited by iron chelators, free radical-trapping antioxidants, GPX4 (Glutathione Peroxidase 4) activators, and lipid peroxidation (LPO) inhibitors. However, the search for new molecular targets for ferroptosis is becoming increasingly important in cardiovascular disease research. In this review, we address the importance of ferroptosis in various cardiovascular illnesses, provide an update on current information regarding the molecular mechanisms that drive ferroptosis, and discuss the role of ferroptosis inhibitors in cardiovascular disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Ferroptosis inhibitors | |
| 650 | 4 | |a antioxidants | |
| 650 | 4 | |a cardiovascular diseases | |
| 650 | 4 | |a iron chelators | |
| 650 | 4 | |a lipoxygenase inhibitors | |
| 650 | 4 | |a reactive oxygen species | |
| 650 | 7 | |a Iron |2 NLM | |
| 650 | 7 | |a E1UOL152H7 |2 NLM | |
| 650 | 7 | |a Phospholipid Hydroperoxide Glutathione Peroxidase |2 NLM | |
| 650 | 7 | |a EC 1.11.1.12 |2 NLM | |
| 700 | 1 | |a Motieian, Shokouh |e verfasserin |4 aut | |
| 700 | 1 | |a Alvandi, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdi, Amirhossein |e verfasserin |4 aut | |
| 700 | 1 | |a Asadzadeh, Bahareh |e verfasserin |4 aut | |
| 700 | 1 | |a Farzipour, Soghra |e verfasserin |4 aut | |
| 700 | 1 | |a Abbasi, Sahar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mini reviews in medicinal chemistry |d 2001 |g 22(2022), 17 vom: 06., Seite 2271-2286 |w (DE-627)NLM121595404 |x 1875-5607 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:17 |g day:06 |g pages:2271-2286 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389557522666220218123404 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 17 |b 06 |h 2271-2286 | ||